Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition
The Firm Forecasts Increased Injectables Momentum In The Second Half Of 2025
Hikma has already raised its generics guidance once before this year • Source: Shutterstock 
